Eiger BioPharmaceuticals initiated with a Buy at B. Riley FBR. B. Riley FBR analyst Madhu Kumar started Eiger BioPharmaceuticals with a Buy rating and $24 price target. The analyst has “reasonable conviction” in the opportunity for the company’s hepatitis and virus franchise.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.